Yes that’s what I was talking to Dr Yo about this is what he said.


“I’ve looked at lenzilumab much more closely- It is a fascinating drug but as a clinician it has a very gray area on when to administer. Give it too early and you suppress the immune system completely”


“Lenz has an interested MOA. It can’t be discounted. But that drug from India- wow. It’s real and they are working on clinical trials in the US.”

We had a long convo about all three MABs.

HGEN will get some attention once the phase 3 is done. I’m assuming if it goes well. I still think Leronlimab will be better and beat them to it.